FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes
出版年份 2022 全文链接
标题
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes
作者
关键词
-
出版物
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
Volume 323, Issue 2, Pages E123-E132
出版商
American Physiological Society
发表日期
2022-06-20
DOI
10.1152/ajpendo.00050.2022
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans
- (2022) Thomas P.J. Solomon et al. PeerJ
- Adipose Tissue Insulin Resistance is Closely Associated with Metabolic Syndrome in Northern Chinese Populations
- (2021) Kun Zhang et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Relationship of obesity to adipose tissue insulin resistance
- (2020) Jiajia Jiang et al. BMJ Open Diabetes Research & Care
- Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes
- (2019) Ralph A DeFronzo et al. Diabetes & Vascular Disease Research
- A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
- (2019) Steven A. Kliewer et al. Cell Metabolism
- A computational solution to improve biomarker reproducibility during long-term projects
- (2019) Feng Feng et al. PLoS One
- Serum Fibroblast Growth Factor 21 Levels Are Positively Associated with Metabolic Syndrome in Patients with Type 2 Diabetes
- (2019) Ruo-Yao Gao et al. International Journal of Endocrinology
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- The Diabetes Gene and Wnt Pathway Effector TCF7L2 Regulates Adipocyte Development and Function
- (2018) Xi Chen et al. DIABETES
- Glucagon-Like Peptide-1 Increases Beta Cell Regeneration by Promoting Alpha- to Beta-Cell Transdifferentiation
- (2018) Young-Sun Lee et al. DIABETES
- Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice
- (2018) Brandon L. Panaro et al. Molecular Metabolism
- How to Measure Adipose Tissue Insulin Sensitivity
- (2017) Esben Søndergaard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans
- (2017) Ricardo J Samms et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
- (2016) Saswata Talukdar et al. Cell Metabolism
- Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus
- (2016) Y. Hu et al. DIABETES & METABOLISM
- Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor
- (2016) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Human FGF-21 Is a Substrate of Fibroblast Activation Protein
- (2016) Andrew L. Coppage et al. PLoS One
- Fibroblast Growth Factor 21 (FGF21) Protects against High Fat Diet Induced Inflammation and Islet Hyperplasia in Pancreas
- (2016) Garima Singhal et al. PLoS One
- Circulating FGF21 proteolytic processing mediated by fibroblast activation protein
- (2015) E. Y. Zhen et al. BIOCHEMICAL JOURNAL
- Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
- (2015) M. A. Abdul-Ghani et al. DIABETES OBESITY & METABOLISM
- Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice
- (2015) Nicholas Douris et al. ENDOCRINOLOGY
- Fructose ingestion acutely stimulates circulating FGF21 levels in humans
- (2015) Jody R. Dushay et al. Molecular Metabolism
- FGF21 Maintains Glucose Homeostasis by Mediating the Cross Talk Between Liver and Brain During Prolonged Fasting
- (2014) Q. Liang et al. DIABETES
- Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients
- (2014) J M Gallego-Escuredo et al. INTERNATIONAL JOURNAL OF OBESITY
- The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
- (2013) Gregory Gaich et al. Cell Metabolism
- High Glucose Represses -Klotho Expression and Impairs Fibroblast Growth Factor 21 Action in Mouse Pancreatic Islets: Involvement of Peroxisome Proliferator-Activated Receptor Signaling
- (2013) W. Y. So et al. DIABETES
- Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs
- (2013) Fiona M. Keane et al. FEBS Open Bio
- Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones
- (2013) Andrew C. Adams et al. Molecular Metabolism
- Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones
- (2012) Paul A. Dutchak et al. CELL
- Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults
- (2012) R D Semba et al. JOURNAL OF HUMAN HYPERTENSION
- Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor
- (2012) W. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial
- (2011) S. L. Samson et al. DIABETOLOGIA
- Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance
- (2011) Clarence Hale et al. ENDOCRINOLOGY
- Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
- (2010) f. M. Fisher et al. DIABETES
- Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
- (2010) Jody Dushay et al. GASTROENTEROLOGY
- Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride
- (2010) Huating Li et al. JOURNAL OF HEPATOLOGY
- Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile
- (2010) Zhuofeng Lin et al. PLoS One
- Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance
- (2009) A. O. Chavez et al. DIABETES CARE
- Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus
- (2009) Ke Li et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes
- (2009) Katsumi Iizuka et al. FEBS LETTERS
- Adipose Fibroblast Growth Factor 21 Is Up-Regulated by Peroxisome Proliferator-Activated Receptor and Altered Metabolic States
- (2008) E. S. Muise et al. MOLECULAR PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now